Profile Picture
  • All
  • Search
  • Images
  • Videos
  • Maps
  • News
  • Copilot
  • More
    • Shopping
    • Flights
    • Travel
  • Notebook
  • Top stories
  • Sports
  • U.S.
  • Local
  • World
  • Science
  • Technology
  • Entertainment
  • Business
  • More
    Politics
Order byBest matchMost fresh
  • Any time
    • Past hour
    • Past 24 hours
    • Past 7 days
    • Past 30 days

Lilly's Next-Gen Drug Tops Zepbound on Weight Loss

Digest more
 · 4d · on MSN
Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial
Dec 11 (Reuters) - Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a late-stage trial, outperforming its blockbuster drug Zepbound and reinforcing the company's lead in the fast-growing market.

Continue reading

 · 3d · on MSN
Lilly Reports Dramatic Weight Loss in Next-Gen Obesity-Drug Trial
 · 3d
Eli Lilly’s Weight Loss Superdrug Worked So Well During Trials, Some Quit Over Losing Too Much
Devdiscourse
1d

Race in Obesity Drugs Heats Up Amidst Legal Battles and Aid Crises

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...
Clinical Pain Advisor
13d

Eli Lilly Becomes First Trillion-Dollar Health Company

Eli Lilly reached a major milestone by becoming the first healthcare company in the world to hit a $1 trillion market value.
Zacks.com on MSN
12d

LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website

Eli Lilly LLY announced that it has lowered the price of single-dose vials of its blockbuster obesity drug, Zepbound ...
6don MSN

2 Potential Stock Splits to Watch for in 2026

After experiencing incredible rallies during 2025, these two stocks could decide to "split it" in 2026.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results
Feedback
  • Privacy
  • Terms